Determination of immunoreactivity of doxorubicin antibody immunoconjugates by a Le(y) competitive RIA.
Many monoclonal antibody-drug immunoconjugates have been evaluated for their ability to deliver cytotoxic drugs to tumors. It is essential to establish that the ability of the conjugates to bind antigen, i.e. their immunoreactivity, is not adversely affected by the drug conjugation procedure. We have described herein a measurement of the immunoreactivity of BR96-DOX, a conjugate comprised of BR96, a chimeric monoclonal antibody specific for the Le(y) tetrasaccharide commonly expressed on human carcinomas, and doxorubicin, an anticancer agent in widespread clinical use. We have employed a competitive RIA, in which microtiter wells were coated with synthetic Le(y) conjugated to human serum albumin and then incubated with 125I-labeled antibody BR96 in the presence of test conjugate or intact BR96 mAb. The test conjugates were found to compete as effectively as unconjugated BR96. This assay is highly applicable to QC processes with the intra-assay CV = 2.0% and the interassay CV = 4.3%.
Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Wallingford, Connecticut 06492.
H
H
Zhao
D
D
Willner
J S
JS
Cleaveland
G R
GR
Braslawsky
J P
JP
Brown
D000911:Antibodies, Monoclonal / Q000378:metabolism*; D000915:Antibody Affinity; D002478:Cells, Cultured; D004317:Doxorubicin / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D016256:Lewis X Antigen / Q000276:immunology*; D011863:Radioimmunoassay
D000911:Antibodies, Monoclonal; D016256:Lewis X Antigen; D004317:Doxorubicin